| Literature DB >> 26264597 |
Chun Li1, Lan-Qing Ying2, Sha-Sha Zhang3,4, Nan Chen5,6, Wei-Feng Liu7, Yong Tao8.
Abstract
BACKGROUND: In engineered strains of Escherichia coli, bioconversion efficiency is determined by not only metabolic flux but also the turnover efficiency of relevant pathways. Methyl-D-erythritol 4-phosphate (MEP)-dependent carotenoid biosynthesis in E. coli requires efficient turnover of precursors and balanced flux among precursors, cofactors, and cellular energy. However, the imbalanced supply of glyceraldehyde 3-phosphate (G3P) and pyruvate precursors remains the major metabolic bottleneck. To address this problem, we manipulated various genetic targets related to the Entner-Doudoroff (ED)/pentose phosphate (PP) pathways. Systematic target modification was conducted to improve G3P and pyruvate use and rebalance the precursor and redox fluxes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26264597 PMCID: PMC4534122 DOI: 10.1186/s12934-015-0301-x
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Genetic targets in central metabolic pathways for MEP-dependent carotenoid biosynthesis.
Fig. 2Effects of deleting different EMP pathway genes on neurosporene biosynthesis. a Relative neurosporene production of W036 (wild type) and P036 (Δpgi) over time; b relative neurosporene production of strains with deletions of different EMP pathway genes after bioconversion for 12 h.
Fig. 3Effects of overexpression of different ED/PP pathway genes on neurosporene biosynthesis. Relative neurosporene production of strains overexpressing different ED/PP pathway genes after bioconversion for 12 h.
Fig. 4Enhanced precursor use by manipulating Dxs and Eda. a Dxs was expressed at different strengths, and neurosporene production was compared between Δpgi strain and wild-type strain after bioconversion for 12 h; b neurosporene production in strain simultaneously expressing Dxs and Eda after bioconversion for 12 h; c neurosporene production in strain in which Dxs and Eda were spatially coupled by protein scaffold after bioconversion for 12 h.
Fig. 5Roles of PP pathway and ED pathway in ED/PP pathway route and balance between PP and ED pathways. a Neurosporene production in strains ΔpgiΔedd and ΔpgiΔgnd after bioconversion for 0 or 12 h; b neurosporene production in strains with different gnd and eda engineering genotypes after bioconversion for 12 h.
Fig. 6Flux balance within EMP pathway and its effects on carotenoid biosynthesis. Neurosporene production in strains with deletions of different EMP pathway targets after bioconversion for 12 h.
Fig. 7Batch fermentation to produce neurosporene in a microbioreactor. Change in relative biomass over time for strains W036 (BW25113 with pLY036), P036 (Δpgi with pLY036), TX036 (PT5-dxs with pLY036), PTX036 (Δpgi PT5-dxs with pLY036), PTXI036 (Δpgi PT5-dxs PT5-idi with pLY036), SXID036 (BW25113 with pSB1s-dxs-idi-ispDF and pLY036), PTXI-SXID036 (Δpgi PT5-dxs PT5-idi with pSB1s-dxs-idi-ispDF and pLY036).
Batch fermentation for neurosporene production in a microbioreactor
| Strain | Biomass (OD600 value) | Neurosporene production (mg neurosporene/g DCW) | Titer (mg neurosporene/L) |
|---|---|---|---|
| W036 | 8.91 | 1.76 | 4.7 |
| P036 | 10.35 | 1.83 | 5.68 |
| TX036 | 16.2 | 2.40 | 11.66 |
| PTX036 | 23.16 | 4.64 | 32.24 |
| PTXI036 | 30.35 | 5.35 | 48.71 |
| W-SXID036 | 17.3 | 4.53 | 23.51 |
| PTXI-SXID036 | 40.47 | 16.69 | 202.64 |
Bioconversion was performed in a microbioreactor for 24 h and biomass and neurosporene production were monitored.
Acetate accumulation and glucose consumption of strains
| Strain | Biomass (OD600) | Acetate production (mg acetate/mL) | Residual glucose (mg glucose/mL) |
|---|---|---|---|
| W036 | 10 | 7.86 | 14.6 |
| P036 | 10.8 | 5.80 | 7.8 |
| W-SXID036 | 13.1 | 2.28 | 0.03 |
| PSX036 | 18.3 | 0.49 | 0 |
| PTXI-SXID036 | 22.6 | 0.21 | 0 |
Strains were cultured in flasks for bioconversion, and acetate accumulation and glucose consumption were monitored.
Fig. 8Lycopene production in strains with ED/PP pathway route. Lycopene production in wild-type strain (W-10RK, BW25113 with pLY10RK), non-ED/PP route strain (TXI-SXID10RK, PT5-dxs PT5-idi with pSB1s-dx -idi-ispDF and pLY10RK), ED/PP route strain (PTXI-SXID10RK, Δpgi PT5-dxs PT5-idi with pSB1s-dx -idi-ispDF and pLY10RK), and final optimal engineered strain (PTXIGK-AEGG-SXID10RK, ΔpgiPT5-dxsPT5-idiΔptsGgalR::P119-glk with pBAD-eda-GCgnd, pSB1s-dxs-idi-ispDF and pLY10RK) after bioconversion for 24 h.
Fig. 9NADPH and G3P generation through different pathway routes. ED/PP pathways routes were created by either Δpgi or ΔpfkAB, resulting in ED + PP1 or ED + PP2. EMP or ED pathway is shown in black; PP pathway is shown in dark gray. NADPH and G3P generation through PP pathways in different routes is summarized in corresponding boxes.
Strains and plasmids used in this study
| Strain/plasmid | Description | References |
|---|---|---|
|
| ||
| BW25113 | Wild type K-12 strain | Our lab |
| DH5αa | For genetic manipulation | Invitrogen |
| TX | PT5- | This study |
| TI | PT5- | This study |
| GRK |
| This study |
| W036 | BW25113, pLY036 plasmid | This study |
| P036 |
| This study, KEIO |
| KA036 |
| This study, KEIO |
| KB036 |
| This study, KEIO |
| KAB036 |
| This study |
| F036 |
| This study, KEIO |
| W-AZ036 | BW25113, pBAD- | This study |
| W-AE036 | BW25113, pBAD- | This study |
| W-AD036 | BW25113, pBAD- | This study |
| TX036 | PT5- | This study |
| PTX036 |
| This study |
| W-SX036 | BW25113, pSB1s- | This study |
| P-SX036 |
| This study, KEIO |
| TX-SX036 | PT5- | This study |
| PTX-SX036 |
| This study |
| P-AE036 |
| This study, KEIO |
| P-A-SEX036 |
| This study, KEIO |
| P-AE-SX036 |
| This study, KEIO |
| P-AS-SEX036 |
| This study, KEIO |
| PD-SX036 |
| This study |
| PG-SX036 |
| This study |
| P-AEG036 |
| This study, KEIO |
| P-AEGG036 |
| This study, KEIO |
| PG036 |
| This study |
| PG-AE036 |
| This study |
| PG-AEG036 |
| This study |
| PG-AEGG036 |
| This study |
| W-SXID036 | BW25113, pSB1s- | This study |
| P-SXID036 |
| This study, KEIO |
| KA-SXID036 |
| This study |
| KAB-SXID036 |
| This study |
| PKAB-SXID036 |
| This study |
| PF-SXID036 |
| This study |
| PY-SXID036 |
| This study |
| PTXI036 |
| This study |
| PTXI-SXID036 |
| This study |
| W10RK | BW25113, pLY10RK plasmid | This study |
| TXI-SXID10RK | PT5- | This study |
| PTXI-SXID10RK |
| This study, KEIO |
| PTXIGK-AEGG-SXID10RK |
| This study, KEIO |
| Other bacterial strains | ||
| |
| Our lab |
| |
| Our lab |
| |
| Our lab |
| |
| Our lab |
| Plasmids | ||
| pKD46 | For lambda-Red mediated recombination | [ |
| pUKM | For lambda-Red mediated recombination, derived from pKD4 by inserting multiple cloning site closed to FRT | Our lab |
| pCP20 | For lambda-Red mediated recombination | [ |
| pUKM-T5 | For construction of TX and TI, derived from pUKM by inserting T5 promoter at multiple cloning site | This study |
| pBAD-HisA | ColE1 origin, | Invitrogen |
| pSB1s | pSC101 origin, | Our lab |
| pS95s | pSC101 origin, constitutive P119 promoter (derived from iGEM part BBa_J23119), StrR | Our lab |
| pS95s- | pSC101 origin, constitutive P119 promoter, StrR, | This study |
| pUKM- | For construction of GRK, derived from pUKM by inserting P119- | This study |
| pLY036 | p15A origin, | This study |
| pLY10RK | RSF1030 origin, | This study |
| pSB1s- | pSC101 origin, | This study |
| pSB1s- | pSC101 origin, | This study |
| pSB1s- | pSC101 origin, | This study |
| pBAD- | ColE1 origin, | This study |
| pBAD- | ColE1 origin, | This study |
| pBAD- | ColE1 origin, | This study |
| pBAD- | ColE1 origin, | This study |
| pBAD- | ColE1 origin, | This study |
| pBAD-SS | ColE1 origin, | This study |